Bacterial polysaccharide–protein conjugate vaccines (Haemophilus influenzae type b [Hib],
pneumococcal and meningococcal conjugates) have revolutionized pediatric vaccination …

Background Routine use of whole‐cell pertussis (wP) vaccines was suspended in some
countries in the 1970s and 1980s because of concerns about adverse effects. Following this …

Objective. To evaluate within the first 6 months of birth the immunogenicity of a 3-component
acellular pertussis (aP) vaccine containing filamentous hemagglutinin (FHA), pertactine …

Pertussis continues to be an important public-health issue. The high immunization coverage
rates achieved, mainly in industrialized countries, have certainly decreased the spread of …

Extensive limb swelling (ELS) has been reported after vaccination with a limited number of
vaccine types. We sought to describe vaccine types involved in and the clinical …

This review offers a perspective on the acellular pertussis vaccine efficiency trials concluded
in the 1990s and presents the main conclusions of a meta-analysis of 52 studies that …

The current diphtheria–tetanus–pertussis (DTP) pediatric vaccine is produced from the
corresponding pathogenic bacteria Corynebacterium diphtheriae, Clostridium tetani and …

Background: The epidemiology of pertussis is changing, with a clear increase in the number
of cases diagnosed in adolescents and adults. This development has spurred studies and …

The widespread use of whole-cell pertussis vaccines in the second half of the 20th century
have reduced the incidence of the disease significantly. However, in some countries …

Objective. Currently, 4 diphtheria-tetanus-acellular pertussis (DTaP) vaccines are licensed
for pediatric use in the United States, and 2 are commercially available. Although a single …